Cooperative Agreement UG3DA062112
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$643K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Cooperative Agreement
Place of Performance
Virginia, USA
Similar Awards
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $6,489,450.00 to New York University to evaluate psilocybin as an adjunctive treatment for opioid use disorder (OUD) in methadone-maintained patients who continue to use illicit opioids. The study will recruit 240 participants from opioid treatment programs in New York and New Mexico, and will provide psilocybin treatment implemented as...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $246,000.00 to The Trustees of Princeton University to investigate the brain mechanisms underlying the therapeutic potential of psilocybin. The research aims to: 1) examine the accelerated acquisition of motivated behavior and task performance after psilocybin administration, and 2) identify the cellular and brain-wide substrates driving...
This federal Project Grant award for $708,511 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) will fund a mechanistic trial to elucidate the effects of psilocybin on neural activity in individuals with alcohol use disorder (AUD). The study aims to evaluate the impacts of high-dose versus low-dose psilocybin on AUD patients' neural response to negative affective stimuli and alcohol cues, as well as subsequent drinking...
This Project Grant award from the National Center for Complementary and Integrative Health (NCCIH), under the federal Research and Training in Complementary and Integrative Health program (CFDA 93.213), will fund a feasibility clinical trial to develop and evaluate a Psilocybin-Assisted Cognitive Behavioral Therapy (PA-CBT) protocol for treating major depressive disorder. The $236,250 award, granted on December 17, 2024, supports a 3-year study to refine and optimize the PA-CBT approach, and...
The National Institute of Mental Health (NIMH) awarded a $679,118 Project Grant (CFDA 93.242 - Mental Health Research Grants) to the University of California, Santa Cruz (UCSC) to study the cellular and circuit mechanisms underlying the long-lasting therapeutic effects of the psychedelic drug psilocybin in the stressed brain. The project aims to determine how psilocybin affects synaptic plasticity, cortical functional networks, and the representation of behavioral variables in the stressed...
This Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $684,694 to New York University School of Medicine to develop and evaluate a telehealth-delivered transcranial direct current stimulation (tDCS) intervention combined with mindfulness meditation for treating cannabis use disorder (CUD). The project, titled "Telehealth-Delivered tDCS for Cannabis Addiction Recovery: The C.A.R.E.S....
This $1,255,890 Project Grant award from the National Institute of Mental Health (NIMH), under the Mental Health Research Grants (CFDA 93.242) program, supports research at Cornell University to investigate the role of cortical GABAergic interneurons in the effects of the psychedelic drug psilocybin. The key objectives are to: 1) use cell type-specific electrophysiology to measure how the three major subtypes of GABAergic interneurons in the mouse medial frontal cortex respond to psilocybin...
This Project Grant award of $702,965 was provided by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The purpose of the award is to conduct a pilot mechanistic study to evaluate the potential of the drug semaglutide, a glucagon-like peptide receptor agonist (GLP-1RA), as a treatment for cocaine use disorder (CUD). The 4-year study, which will run from June 2025 to February 2029, will assess semaglutide's impact on key...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), is funding a $1,585,991 study to evaluate the efficacy of combining transcranial direct current stimulation (tDCS) with cognitive reappraisal training to reduce craving and reactivity to drug cues in individuals with cocaine use disorder. The study, being conducted at the Icahn School of Medicine at Mount Sinai, will perform a double-blind...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is funding research at the University of Oregon to investigate the polypharmacology and psychoplastogenic effects of psychedelic drugs using the C. elegans model organism. The overarching goal is to determine how representative psychedelic compounds, which primarily activate serotonin receptors, influence behavior and neuroplasticity in this invertebrate...